![]() ![]() “XIAFLEX is already available in the U.S. “We are excited to announce this strategic collaboration with Actelion, which will further enable XIAFLEX to reach patients around the world who are in need of this treatment,” reflected Thomas L. Actelion will be primarily responsible for the applicable regulatory and commercialization activities for XIAFLEX in these countries. Under this agreement, Actelion will receive exclusive rights to commercialize XIAFLEX for the two indications in Canada, Australia, Brazil and Mexico upon receipt of the respective regulatory approvals. (Actelion) for the long-term development, supply and commercialization of XIAFLEX for the treatment of Dupuytren’s contracture and Peyronie’s disease. (Auxilium) has entered into a partnership with Actelion Pharmaceuticals Ltd. and XIAPEX ® in Europe and Eurasia, today announced that its partner Auxilium Pharmaceuticals, Inc. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX ® in the U.S. February 23, 2012) - BioSpecifics Technologies Corp. Company Overview Our Team Our Commitment Success Stories Upcoming Conferences CareersīioSpecifics Announces Partnership Between Auxilium and Actelion for XIAFLEX(R) in Canada, Australia, Brazil and Mexico.We’ll see how AUXL’s board plays its hand….Click here for a free trial to The Health Care M&A Information Source and download the current issue today. (NASDAQ: QLTI) for $342 million, and paid $585 million for Actient Pharmaceuticals, LLC in April 2013. In June it executed a reverse takeover of QLT, Inc. Auxilium, a specialty biopharma based in Chesterbrook, Pennsylvania, has been a busy acquirer in its own right. The $2.2 billion total price represents an offer of $28.10 in cash and stock, a 31% premium to Auxilium’s closing price on September 16, 2014. Endo International plc (TSX: ENL), formerly of the United States and now domiciled in Dublin, Ireland, made an unsolicited bid for Auxilium Pharmacetuicals, Inc. company moving abroad, because the would-be acquirer already did that. This one, for once, isn’t all about a U.S. Welsh, Carson will hold a majority of the shares.Įndo’s Bid for Auxilium Isn’t an Inversion ![]() The price includes $360 million in cash and 946,722 shares of Providence common stock with a value of $40 million as of the close of trading on Sept. It is a portfolio company of Welsh, Carson, Anderson & Stowe XI, LP. Matrix Medical operates in 33 states, through a national network of nurse practicitioners serving Medicare Advantage members. Providence Service Corporation (NASDAQ: PRSC) got into the home health care business with its $400 million acquisition of Matrix Medical Newtork (aka CCHN Group Holdings, Inc.), which provides in-home health assessment and care management services. ![]() Welsh, Carson Releases Matrix Medical Network Source: The Health Care M&A Information Source, September 18, 2014 Top 5 Biotechnology Deals thru September 18, 2014 ![]() (Biotech ended 2013 with 83 and total spending of $29.6 billion.) We still have the fourth quarter to go, too. Take that ringer out of the mix, and deal value would have been just $11.3 billion for the same time period. That deal was also the largest announced in 2013. In the same period last year, Biotech deal value was already $26.5 billion, thanks to Thermo Fisher Scientific’s (NYSE: TMO) $15.1 billion acquisition of Life Technologies (NASDAQ: LIFE) in April 2013. 18th, Biotech deal values hit $18.56 billion, with 45 of the 84 deals reported prices. Spending has been strong, as well, even though the billion-dollar acquisitions haven’t been in the double-digit range. Last year’s total deal count was 83 deals, so this sector is on track to do even better by December 31. In fact, it’s been moving along quite well this year, with 84 deals announced through September 18th. With all the brouhaha over the mega-deals in the Pharmaceutical category, it’s seems that the Biotech M&A market has been quiet. And, presumably, keeping TriZetto’s clients, too. It’s expecting to realize about $1.5 billion of revenue synergies over the next five years. Healthcare represents about 26% of Cognizant’s revenue. health plans and four of the top five pharmacy benefit management companies. TriZetto and its 3,700 employees will join Cognizant’s existing healthcare business unit, which counts more than 200 clients, including 16 of the top 20 U.S. (then under the NASDAQ ticker symbol TZIX) private. You may recall that, in April 2008, Apax Partners, LP paid $1.4 billion to take TriZetto Group, Inc. Last week, IT services giant Cognizant (NASDAQ: CTSH) bet big on the health care industry with its $2.7 billion acquisition of TriZetto Corporation, which specializes in healthcare IT software and solutions. Cognizant Boosts Its Health Care Biz with TriZetto Deal ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |